Wheeler, D C, Stefansson, B V, Batiushin, M, Bilchenko, O, Cherney, D Z I, Chertow, G M, Douthat, W, Dwyer, J P, Escudero, E, Pecoits-Filho, R, Furuland, H, Górriz, J L, Greene, T, Haller, H, Hou, F F, Kang, S W, Isidto, R, Khullar, D, Mark, P B, McMurray, J J V, Kashihara, N, Nowicki, M, Persson, F, Correa-Rotter, R, Rossing, P, Toto, R D, Umanath, K, Van Bui, P, Wittmann, I, Lindberg, M, Sjöström, C D, Langkilde, A M & Heerspink, H J L 2020, ' The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial : baseline characteristics ', Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association, vol. 35, no. 10, pp. 1700-1711 . https://doi.org/10.1093/ndt/gfaa234 Nephrology Dialysis Transplantation Nephrology Dialysis Transplantation, 35(10), 1700-1711. Oxford University Press Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname